tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MLYS Stock Latest News

Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial
The FlyMineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial
13d ago
MLYS
Insiders Pour Millions into These 2 Stocks — Goldman Sachs Backs the Move
PremiumStock Analysis & Ideas
Insiders Pour Millions into These 2 Stocks — Goldman Sachs Backs the Move
27d ago
SFD
MLYS
Mineralys Therapeutics falls -4.9%
PremiumThe Fly
Mineralys Therapeutics falls -4.9%
28d ago
MLYS
Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
PremiumThe Fly
Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
1M ago
MLYS
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
PremiumRatings
Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position
1M ago
MLYS
Buy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
PremiumRatingsBuy Rating Affirmed for Mineralys Therapeutics Due to Promising Hypertension Drug Data and Market Position
1M ago
MLYS
Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial
Premium
The Fly
Mineralys announces new subgroup analyses from Phase 3 Launch-HTN trial
1M ago
MLYS
Mineralys Therapeutics Announces Public Offering of Shares
Premium
Company Announcements
Mineralys Therapeutics Announces Public Offering of Shares
1M ago
8K
MLYS
Mineralys Therapeutics 9.8M share Spot Secondary priced at $25.50
PremiumThe Fly
Mineralys Therapeutics 9.8M share Spot Secondary priced at $25.50
1M ago
MLYS
Mineralys Therapeutics Halts Common Stock Offering
PremiumCompany Announcements
Mineralys Therapeutics Halts Common Stock Offering
1M ago
8K
MLYS
Mineralys Therapeutics announces $175M common stock offering
PremiumThe Fly
Mineralys Therapeutics announces $175M common stock offering
1M ago
MLYS
3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
1M ago
BBIO
MLYS
Jefferies expects Mineralys stock to trade up following AstraZeneca data
PremiumThe FlyJefferies expects Mineralys stock to trade up following AstraZeneca data
1M ago
MLYS
Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
Premium
Ratings
Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
1M ago
MLYS
Mineralys Therapeutics, Inc. Earnings Call Highlights
Premium
Company Announcements
Mineralys Therapeutics, Inc. Earnings Call Highlights
1M ago
MLYS
Mineralys Therapeutics price target raised to $43 from $38 at BofA
PremiumThe Fly
Mineralys Therapeutics price target raised to $43 from $38 at BofA
2M ago
MLYS
3 Best Stocks to Buy Now, 8/14/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 8/14/2025, According to Top Analysts
2M ago
BTM
EXE
Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position
PremiumRatings
Positive Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Lorundrostat Outcomes and Strong Financial Position
2M ago
MLYS
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond
PremiumRatings
Buy Rating on Mineralys Therapeutics: Promising Outcomes for Lorundrostat in Hypertension and Beyond
2M ago
MLYS
Mineralys Therapeutics Reports Positive Q2 2025 Results
PremiumCompany AnnouncementsMineralys Therapeutics Reports Positive Q2 2025 Results
2M ago
MLYS
Mineralys Therapeutics, Inc. (MLYS) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Mineralys Therapeutics, Inc. (MLYS) Q2 Earnings Cheat Sheet
2M ago
MLYS
3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
3M ago
MLYS
PRAX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >